Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer

Overview of attention for article published in Lung Cancer: Targets and Therapy, December 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#17 of 128)
Good Attention Score compared to outputs of the same age (79th percentile)

Mentioned by

twitter: 15 X users

Citations

dimensions_citation: 18 Dimensions

Readers on

mendeley: 27 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 18 publications that cite this research output.

18

The most recent citing publications are shown below. View all 18 publications that cite this research output on Dimensions.

Novel therapeutic strategies for rare mutations in non-small cell lung cancer

Article in Scientific Reports (May 2024)

Modeling the subcutaneous pharmacokinetics of antibodies co‐administered with rHuPH20

Article in Clinical and Translational Science (April 2024)

Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC)

Article in Translational Lung Cancer Research (December 2023)